ADHD Medication Use in Pregnant Adolescents

Introduction to Medication Safety

• The American College of Obstetricians and Gynecologists recommends guanfacine be used with caution in pregnancy due to limited safety data, with the single small study showing concerning rates of low birth weight 3
• Guanfacine could be considered in ADHD treatment following a risk-benefit discussion acknowledging the very limited information on its safety in pregnancy, but alternative agents would be preferred 1, 2

Medication Selection and Management

• If medication is necessary, the preferred choice is methylphenidate or amphetamines, followed by atomoxetine, and lastly guanfacine due to minimal data 1, 2
• For guanfacine, consideration should be given to switching to atomoxetine or methylphenidate due to the absence of pregnancy-specific ADHD data and the 20% low birth weight rate in the single hypertension study 1, 2, 3

Patient Care and Monitoring

• Adolescent pregnancies carry inherently higher risks, making medication decisions even more complex, and comprehensive prenatal care coordination is essential 1
• Ensure monitoring of fetal growth closely given the low birth weight signal with guanfacine and modest preterm birth risk with atomoxetine 1

Special Considerations

• There is no safety data on the combination of atomoxetine and guanfacine during pregnancy, and simplifying to monotherapy with the safest option is recommended 1, 2
• If planning to breastfeed, note that guanfacine has no published breastfeeding studies, while atomoxetine appears in breast milk but at very low concentrations in infant blood 1, 2